Addressing the issue of whether a generic pharmaceutical company can be found to induce infringement even when all patented uses have been “carved out” of the label (resulting in a so-called “skinny label”), the US Court of...more
10/15/2020
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Carve Out Provisions ,
Circumstantial Evidence ,
Induced Infringement ,
Jury Verdicts ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prescription Drugs ,
Teva Pharmaceuticals